TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED
(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)
(Incorporated in the People's Republic of China)
(Company Registration No.: 91120000103100784F)

CONTINUOUS RISK ASSESSMENT REPORT OF TIANJIN PHARMACEUTICAL GROUP FINANCE CO., LTD. (天津医药集团财务有限公司)

The board of directors (the "Board") and every individual director of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited) (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Board refers to the announcements made by the Company on 30 March 2022, 12 August 2022, 31 March 2023, 14 August 2023, 29 March 2024, 14 August 2024, 28 March 2025, 14 August 2025 and 30 March 2026 in relation to the previous continuous risk assessment reports of Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) ("**TPGF**") (the "**Previous Announcements**").

Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meanings ascribed to them in the Previous Announcements.

As disclosed in the Previous Announcements, the Shanghai Stock Exchange (the "**SSE**") imposed new requirements in 2022 on companies listed on the SSE, whereby a listed company which has entered into transaction(s) with its related finance company(ies) is required to prepare and publish a continuous risk assessment report on such finance company(ies) on a semi-annual basis.

In 2016, the Company first entered into a financial service agreement with TPGF, a subsidiary of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司), the controlling shareholder of the Company as at the date of this announcement, and therefore a related finance company, pursuant to which TPGF agreed to provide the Company with certain financial services, including settlement and intermediary business services, deposit business services and credit business services (such as the provision of loans to the Company). Save for the first financial services agreement, which was entered into on 30 December 2016 for a term of six (6) months, the financial services arrangements between the Company and TPGF have since been renewed on a triennial basis, with each renewal superseding the preceding agreement. The most recent financial services agreement between the Company and TPGF was entered into on 1 July 2026 for a period of three (3) years from 1 July 2026 to 30 June 2029 (the "**2026 TPGF Agreement**"),[1] which was approved by the shareholders of the Company at the annual general meeting for the financial year ended 31 December 2025.

Please refer to **Appendix A** to this announcement for further details of the continuous risk assessment report of TPGF for the six (6)-month period ended 30 June 2026.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
14 August 2026

[1] For further details of the 2026 TPGF Agreement, please refer to the annexure dated 30 April 2026 to the notice of annual general meeting for the financial year ended 31 December 2025.

APPENDIX A

CONTINUOUS RISK ASSESSMENT REPORT OF TIANJIN PHARMACEUTICAL GROUP FINANCE CO., LTD.
天津医药集团财务有限公司风险评估报告

1. INFORMATION ON TPGF
一、财务公司基本情况

1.1 Information on TPGF
财务公司基本信息

Upon approval by the China Banking and Insurance Regulatory Commission (中国银行保险监督管理委员会) (now known as the National Financial Regulatory Administration (国家金融监督管理总局) (the "**NFRA**")), Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司) ("**TPGF**") was incorporated on 14 September 2016 with a registered capital of RMB500 million, jointly contributed by: (i) Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("**TPH**"); (ii) the Company; (iii) Tianjin Lisheng Pharmaceutical Co., Ltd. (天津力生制药股份有限公司); (iv) Tianjin Yaoye Group Co., Ltd. (天津药业集团有限公司) ("**Yaoye Group**"); and (v) Tianjin Jin Yi Investment Guarantee Co., Ltd. (天津金益投资担保有限责任公司) ("**Jin Yi Investment**"). As at the date of this announcement, the shareholders of TPGF are TPH, the Company, Yaoye Group, and Jin Yi Investment, and TPGF is under the supervision of the NFRA.
财务公司经国家金融监督管理总局批准，于2016年9月正式成立，由天津市医药集团有限公司、津药达仁堂集团股份有限公司、天津药业集团有限公司和天津金益投资有限公司共同出资设立，依法接受国家金融监督管理总局监管。

Further details of TPGF as at the date of this announcement are set out below.

Name of Company 公司名称	:	Tianjin Pharmaceutical Group Finance Co., Ltd. (天津医药集团财务有限公司)
Registered Address 注册地址	:	3-2-501/502, 3-3-501 Ronghe Square, No. 168 Fourth West Road, Tianjin Pilot Free-Trade Zone (Airport Economic Area) (天津自贸试验区 (空港经济区) 西四道168号融和广场3-2-501/502; 3-3-501)
Legal Representative 法定代表人	:	Mr. Xing Jianhua (幸建华)
Finance License Institution Code 金融许可证机构编码	:	L0248H212000001
Uniform Social Credit No. 统一社会信用代码	:	91120118MA05L0R67F
Registered Capital 注册资本	:	RMB1,000 million 10亿元人民币
Business Scope 财务公司经营范围	:	Absorbing deposits from the member entities of TPH group; providing loans to the member entities of the TPH group; conducting discounting of negotiable instruments for the member entities of the TPH group; providing fund settlement, receipt and payment services for the member entities of the TPH group; providing entrusted loans, bond underwriting, non-

__Disclaimer:__ The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.

financing guarantees, financial advisory services, credit attestation services, and consultancy and agency services to member entities of the TPH group; engaging in inter-bank borrowings; handling acceptance of negotiable instruments for the member entities of the TPH group; and engaging in fixed income securities investment
财务公司经营范围：吸收成员单位存款；办理成员单位贷款；办理成员单位票据贴现；办理成员单位资金结算与收付；提供成员单位委托贷款、债券承销、非融资性保函、财务顾问、信用鉴证及咨询代理业务；从事同业拆借；办理成员单位票据承兑；从事固定收益类有价证券投资

1.2 Shareholdings in TPGF
财务公司股东名称、出资金额和出资比例

As at the date of this announcement, the shareholdings in TPGF are as follows:

No. 序号	Name of Shareholder 股东名称	Equity Contribution 认缴金额 (RMB)	Shareholding Percentage 股权比例 (%)
1.	TPH	500 million	50%
2.	The Company	300 million	30%
3.	Yaoye Group	150 million	15%
4.	Jin Yi Investment	50 million	5%

2. INFORMATION ON INTERNAL CONTROL OF TPGF
财务公司内部控制的基本情况

2.1 Governance Structure
控制环境

In accordance with the provisions of the *Company Law of the People's Republic of China (《中华人民共和国公司法》)* (the "**PRC Company Law**") and its articles of association, TPGF has established a governance structure comprising (i) the shareholders (acting in a shareholders' meeting), (ii) the board of directors, (iii) the board of supervisors, and (iv) the management. The respective responsibilities of each governance body are clearly defined and are in line with the principles of independent operation and effective check and balance. The roles and responsibilities of the board of directors, supervisors and senior management in respect of internal control are also clearly stipulated. The shareholders (acting in a shareholders' meeting) are the highest decision-making authority of TPGF. The board of directors is responsible for determining major matters of TPGF and accountable to the shareholders, while the management team, under the leadership of the general manager, is responsible for the day-to-day operations of TPGF. TPGF has a sound governance structure and standardised management and operations, and has established an organisational structure with a reasonable division of responsibilities, clearly defined accountabilities and clear reporting lines, thereby providing the necessary foundation for effective risk management.
财务公司按照《公司法》和公司章程的规定，设立三会一层治理架构，各治理主体职责边界清晰，符合独立运转、有效制衡原则，并对董事会和董事、监事、高级管理层在内部控制中的责任进行了明确规定，股东会是财务公司最高决策者，董事会决定财务公司重大事项，向股东会负责，总经理领导下的经营班子负责财务公司的日常运营。财务公司治理结构健全，管理运作规范，建立了分工合理、责任明确、报告关系清晰的组织结构，为风险管理的有效性提供了必要的前提条件。

As at the date of this announcement, the organisational structure of TPGF is as follows:

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*

组织架构图如下：



2.2 Risk Identification and Assessment
风险的识别与评估

TPGF has established a sound internal control system, which has been effectively implemented. Since its establishment, TPGF has set up an independent risk management department and an audit department, which, together with the front-line business department, form an effective three lines of defence for risk management, thereby enabling comprehensive risk management, supervision and internal audit of TPGF's business activities. Under this framework, the three lines of defence, in accordance with the "Measures for Comprehensive Risk Management of Tianjin Pharmaceutical Group Finance Co., Ltd." (《天津医药集团财务有限公司全面风险管理办法》), identify and assess relevant risks within the scope of their respective responsibilities, and formulate corresponding risk control systems, operational procedures and risk response measures based on the results of such assessments and business characteristics. The responsibilities of each department are clearly segregated, with mutual checks and supervision in place. Through such structure, TPGF has developed sound risk identification and assessment capabilities, enabling it to anticipate, assess and control risks effectively.
财务公司的内部控制制度完善，执行有效，自成立以来，设立了独立的风险管理部和审计稽核部，与前台业务部门形成有效的风险管理三道防线，满足对业务活动进行全方位风险管理和监督稽核的需求。三道防线依据《天津医药集团财务有限公司风险管理办法》，在其职责范围内对相关风险进行识别与评估，并根据评估结果及业务特点制定相应的风控制度、操作流程和风险应对措施，各部门职责分离、相互制约、相互监督，共同构建风险识别和评估能力，对风险进行预测、评估和控制。

2.3 Risk Control
控制活动

TPGF has, in light of its actual operations and management, formulated practical and feasible internal control objectives and implemented an internal control policy that takes into account comprehensive coverage, materiality, checks and balances, prudence and cost-effectiveness. Such internal control objectives and policy are intended to ensure (i) compliance with relevant laws, regulations and regulatory requirements of the People's Republic of China (the "**PRC**"), (ii)

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*

the realisation of TPGF's development strategy and operational objectives, (iii) the effectiveness of TPGF's risk management, and (iv) the truthfulness, accuracy and completeness of TPGF's business records, accounting information, financial information and other management information.
财务公司从经营管理实际出发，制定了切实可行的内部控制目标，实行全覆盖、重要性、制衡性、审慎性与成本效益兼顾的内部控制政策。保证国家有关法律法律及监管制度能够贯彻执行、财务公司发展战略和经营目标顺利实现、风险管理有效；保证财务公司业务记录、会计信息、财务信息和其他管理信息真实、准确和完整。

2.3.1 Fund Management
资金管理

As a non-bank financial institution, TPGF places strong emphasis on fund management and has established the following risk management measures: (i) closely monitoring liquidity ratios, the scale of deposits and loans and their changing trends, and monitoring liquidity risk with reference to the liquidity risk indicators under the "1104" reporting system of the NFRA; (ii) strengthening the management of credit operations and improving the overall quality of credit assets, so as to prevent potential liquidity risks arising from non-performing loans; (iii) optimising the structure of reserve assets and establishing diversified liquidity reserves, with flexible allocation of money market funds and interbank deposits to provide strong support in response to liquidity shocks; (iv)continuously improving and enhancing the prevention, early-warning and response mechanisms for liquidity management, and, through measures such as cash flow management, intraday and medium- to long-term liquidity monitoring, stress testing and contingency planning, optimising the structure and maturity profile of assets and liabilities, broadening financing channels and maintaining reserves of high-quality liquid assets, so as to strengthen fund risk prevention and control on a comprehensive basis and effectively ensure overall funding sufficiency, orderly fund allocation and safe operations; and (v) strengthening comprehensive credit management with peer institutions to provide support and safeguards for TPGF's business operations.
财务公司作为非银行金融机构，十分关注资金管理工作，建立了明确的风险管理措施：一是密切关注流动比率、存贷款规模及其变动趋势，结合国家金融监督管理总局 1104 报表体系中的流动性风险指标对流动性风险进行监测；二是加强信贷业务管理，努力提高信贷资产整体质量，防止因不良贷款而造成信贷资产流动性缺失；三是优化储备资产结构，建立多手段的流动性准备，灵活配置货币基金、同业存款，为应对流动性冲击提供有力保障；四是不断改进和提升流动性管理的防范、预警和处置体系，通过现金流管理、日间及中长期流动性监测、压力测试及应急计划等手段，优化资产负债结构及期限，拓宽融资渠道，储备优质流动性资产，全方位织密资金风险防控网，切实保障整体资金充裕、调度有序、运转安全；五是加强与同业机构之间的综合授信管理，为财务公司的业务开展提供支持和保障。

2.3.2 Credit Management
信贷管理

The internal control of TPGF's credit business focuses on preventing and controlling credit risk, improving the quality of credit assets and optimising the structure of credit assets. For each category of credit business, TPGF has formulated specific management measures and operational procedures. In carrying out its credit business, TPGF strictly determines the credit line to be granted to each member entity of the TPH group based on the relevant member entity's financing balance and financing needs, taking into account TPGF's financial position and in accordance with the requirements of credit management, and strictly conducts its credit business within the approved credit line. In this way, risks are strictly controlled, so that the credit business can be carried out in a planned and balanced manner. At the same time, TPGF implements a three-step credit review system comprising pre-loan investigation, mid-loan review and post-loan inspection, so as to strictly control the risks of its credit business.
财务公司信贷业务的内控重点是防范和控制信用风险，提高信贷资产质量，优化信贷资产结构。针对每类信贷业务，财务公司均制定了具体的管理办法和操作流程，在具体业务开展时，严格根

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*

据授信管理要求，根据成员单位的融资余额及融资需求，结合财务公司资金状况，确定客户授信额度，并严格在授信额度内办理信贷业务，严控风险，使业务的开展既有计划性又有均衡性。同时，财务公司信贷业务执行三查制度，做到贷前调查、贷中审查、贷后检查，严格控制信贷业务风险。

2.3.3 Settlement Business
结算业务

TPGF has formulated internal rules, systems and business operating procedures for its settlement business, including the "Administrative Measures for Settlement Business of Tianjin Pharmaceutical Group Finance Co., Ltd." (《天津医药集团财务有限公司结算业务管理办法》) and the "Business Continuity Plan for Settlement Business" (《结算业务连续性计划》). These are implemented in accordance with the principles of unified management, hierarchical authorisation, clearly defined rights and responsibilities, and the strict implementation of internal control measures in line with regulatory requirements, so as to ensure that personnel responsible for settlement business strictly carry out operations in accordance with the operating procedures, and are prohibited from operating beyond their authority or outside their designated duties, thereby safeguarding the safe conduct of the settlement business and the safety of settlement funds.
财务公司制订了《天津医药集团财务有限公司结算业务管理办法》、《结算业务连续性计划》等制度及业务操作流程，遵循统一管理、分级授权、权责明确、严格按照监管要求落实各项内控措施，确保结算业务人员严格按照操作规程进行操作，严禁越权、越岗操作，保障了结算业务的安全开展和结算资金的安全。

Meanwhile, TPGF strictly follows the principles of equality, voluntariness, fairness and good faith in handling deposit business for member entities of the TPH group. The relevant policies are implemented strictly in accordance with the applicable requirements of the NFRA and the People's Bank of China, so as to fully safeguard the safety of funds of the member entities of the TPH group and protect the legitimate rights and interests of all parties concerned.
同时，财务公司严格遵循平等、自愿、公平和诚实信用的原则为成员单位办理存款业务，相关政策严格按照国家金融监督管理总局和中国人民银行相关规定执行，充分保障成员单位资金的安全，维护各当事人的合法权益。

2.3.4 Internal Audit and Supervision
内部稽核监督

TPGF has established an independent audit department to perform audit and inspection functions in respect of its operating activities and business operations. The audit department of TPGF is responsible for: (i) formulating and organising the implementation of various audit work plans in accordance with the audit requirements of the regulatory authorities; (ii) conducting audit inspections on the legality and compliance of various business activities, and correcting errors and preventing irregularities in a timely manner; and (iii) examining, supervising and evaluating the soundness and effectiveness of TPGF's internal control system, so as to reinforce accountability for internal control management and strengthen the foundation for compliant operations and risk prevention and control.
财务公司单独设立审计稽核部，对经营活动和业务运作行使审计、稽核职能。根据监管机构审计要求，制订并组织实施各项审计稽核工作计划；对各项业务活动的合法合规性进行稽核检查，及时纠错防弊；对内控制度的健全性、有效性进行检查、监督、评价，压实内控管理责任，筑牢合规经营与风险防控根基。

2.3.5 Information System Control
信息系统控制

TPGF has adopted an approach of "overall planning and step-by-step implementation" in the development of its information systems, and has established core business modules including

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*

online financial services, credit management, capital management, investment management, financial management and regulatory reporting. From fund settlement, credit management and notes management, to bank-enterprise direct connection and interfaces with the TPH group's financial system and other business systems, and from financial reporting to fund monitoring, TPGF's information system meets the comprehensive business needs of member entities of the TPH group for centralised fund management and has achieved the centralisation and sharing of information between the core business system and other business systems. TPGF continuously improves and expands its information systems in response to new business needs and developments. It has embedded key internal control points and relevant regulatory requirements into its information systems, embedded its risk control processes through digital means, incorporated compliance controls into its systems and automated day-to-day risk management, thereby comprehensively meeting applicable industry regulatory and internal governance requirements.
财务公司信息系统建设采用了"整体规划、分步实施"的总体建设思路, 核心业务已建成网上金融服务、信贷管理、资金管理、投资管理、财务管理、监管报送等主要业务板块，从资金结算、信贷管理到票据管理，从银企直联到与集团财务系统及其他业务系统接口，从报表到资金监控，满足了成员企业对资金集中管理的全方位业务需求，实现了核心业务系统与其他业务系统信息的集中与共享。财务公司根据新需求、新业务不断对信息系统进行完善和扩充，同时将内部控制及监管法规的主要关键点嵌入信息系统，以数字化手段固化风控流程，实现合规管控内嵌化、日常风控自动化，全方位适配行业监管与内部治理各项要求。

In 2024 and 2025, TPGF progressively upgraded its data centre equipment and related facilities and deployed a disaster recovery centre, further enhancing the role of information technology in supporting its operations. In 2025, in accordance with regulatory requirements relating to data management, TPGF formulated a data governance work checklist and enhanced information technology security in various areas, including data security management, data classification and grading, data protection, and security management responsibilities. In the first half of 2026, TPGF replaced the uninterruptible power supply (UPS) units and the environmental and equipment monitoring system in its data centre, and revised relevant policies relating to data security management, bastion hosts and other key information systems, thereby further strengthening safeguards for network, data and data-centre operational security, and enhancing the stability of data-centre operations and the standardisation of information security management.
2024-2025 年财务公司陆续对数据中心机房等设备进行更新，并部署了灾备中心，进一步强化了信息科技赋能生产经营；同时，2025 年根据监管制度中关于数据管理的要求，制定数据治理工作清单，在数据安全管理、数据分类分级与保护、安全管理责任等多方面确保信息科技的安全；2026 年上半年财务公司对机房 UPS 主机和动环监控系统进行了更换, 并针对数据安全管理、堡垒机等重要信息系统相关制度进行了修订，有效筑牢网络、数据及机房运行安全屏障，进一步提升机房运维稳定性与信息安全规范化管理水平。

2.4 Overall Assessment of Risk Management
风险管理总体评价

All businesses of TPGF have been carried out strictly in accordance with the applicable regulatory requirements and internal rules and procedures. TPGF has a sound management system, its business operations are lawful and compliant, and no major operational risk has occurred. All regulatory indicators for the first half of 2026 were in compliance with the applicable regulatory requirements, and TPGF continued to maintain a good record of zero non-performing assets and non-performing loans. Since 2025, TPGF has continued to explore the application of artificial intelligence in risk monitoring and has independently developed a risk monitoring system. The system conducts routine daily checks and monitoring of key business data and fund receipts and payments, promptly identifies abnormal data or fluctuations for early warning and assessment, and facilitates appropriate follow-up actions, thereby gradually establishing an intelligent, round-the-clock and closed-loop fund risk management and control framework.
财务公司的各项业务均能严格按照监管要求和制度开展，管理制度健全、业务运营合法合规，无重大操作风险发生，2026 年上半年各项监管指标均符合监管的要求，持续保持不良资产、不良贷款"零发生"的良好记录。财务公司自 2025 年以来不断探索人工智能在风险监测方面的应用，自

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*

主研发风险监测系统，每天对关键业务数据、资金收支情况进行常态化核查和监测，及时捕捉异常数据或波动情况进行预警研判、妥善处置，逐步构建起智能化、全天候、闭环式的资金风险管控体系。

3. BUSINESS MANAGEMENT AND RISK MANAGEMENT OF TPGF
财务公司经营管理及风险管理情况

3.1 Key Financial Information
财务公司主要财务数据

Items	As at 31 December 2025 截至最近一年 2025 年 12 月 31 日 (audited) (经审计) (RMB'000)	As at 30 June 2026 截至最近一期 2026 年 6 月 30 日 (unaudited) (未经审计) (RMB'000)
Total assets	4,615,520.8	4,480,518.2
Total liabilities	3,471,842.6	3,313,723.6
Net assets	1,143,678.2	1,166,794.6
Asset-liability ratio	75.22%	73.96%
Items	**January to December 2025 最近一年年度 2025 年度 (audited) (经审计) (RMB'000)**	**January to June 2026 最近一期 2026 年 1 月-6 月 (unaudited) (未经审计) (RMB'000)**
Revenue	65,751.6	28,053.2
Net profit/(loss)	24,191.1	33,116.3

3.2 Management of TPGF
财务公司管理情况

Since its incorporation, TPGF has adhered to the principle of prudent operation, standardised its business operations and strengthened its internal management in accordance with applicable laws and regulations of the People's Republic of China, including the PRC Company Law, the *Accounting Standards for Enterprises (《企业会计准则》)*, the *Measures for the Administration of the Finance Companies of Enterprise Groups (《企业集团财务公司管理办法》)* (the "**Administrative Measures**"), other relevant financial laws and regulations of the PRC, as well as TPGF's articles of association. Based on the Company's understanding and evaluation of the risk management of TPGF, as at 30 June 2026, no material defects have been identified in the risk control systems relating to funds, credit, audit and information management in connection with the financial statements.
自成立以来，财务公司一直坚持稳健经营的原则，严格按照《中华人民共和国公司法》《企业会计准则》《企业集团财务公司管理办法》和国家有关金融法规、条例以及《公司章程》规范经营行为，加强内部管理。根据对财务公司风险管理的了解和评价，截至 2026 年 6 月 30 日日未发现与财务报表相关资金、信贷、审计稽核、信息管理等风险控制体系存在重大缺陷。

3.3 Regulatory Indicators of TPGF
财务公司监管指标

Indicator	TPGF's Ratio 财务公司对应指标	Regulatory Requirement 监管要求

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*

Capital adequacy ratio 资本充足率	33.47%	≥10.5%
Liquidity ratio 流动性比例	76.27%	≥25%
Loans / (Deposits + Paid-in Capital) 贷款余额/存款余额与实收资本之和	41.84%	≤80%
Total external liabilities of the group / Net capital 集团外负债总额/资本净额	0%	≤100%
Bill acceptance balance / Total assets 票据承兑余额/资产总额	3.35%	≤15%
Bill acceptance balance / Interbank deposits 票据承兑余额/存放同业余额	8.16%	≤300%
Total bill acceptance and discounted bills / Net capital 票据承兑和转贴现总额/资本净额	12.26%	≤100%
Bank acceptance margin balance / Total deposits 承兑汇票保证金余额/存款总额	0.23%	≤10%
Total investments / Net capital 投资总额/资本净额	53.64%	≤70%
Net fixed assets / Net capital 固定资产净额/资本净额	1.55%	≤20%

According to the Administrative Measures, as at 30 June 2026, all regulatory indicators of TPGF were within a reasonable range, and no major risk was identified.
根据《企业集团财务公司管理办法》规定，截至 2026 年 6 月 30 日日，财务公司的各项监管指标均在合理的范围内，不存在重大风险。

4. COMPANY’S DEPOSITS WITH, AND LOANS FROM TPGF
上市公司在财务公司存贷款情况

As at 30 June 2026, the Company’s deposit balance with TPGF was approximately RMB1,359 million, and its loan balance with TPGF was nil. The Company’s deposits with TPGF were safe and had good liquidity, and there had been no delay in payment by TPGF due to any shortfall in its cash position.
截至 2026 年 6 月 30 日，公司在财务公司的存款余额约为 13.59 亿元人民币，在财务公司的贷款余额为 0。公司在财务公司的存款安全性和流动性良好，未发生财务公司因现金头寸不足而延迟付款的情况。

5. CONTINUOUS RISK ASSESSMENT MEASURES
持续风险评估措施

The Company conducts prudent due diligence on the relevant business qualification certificates of TPGF, and obtains a comprehensive understanding of TPGF’s organisational structure, institutional framework, and operational activities, so as to strengthen its risk assessment and dynamic monitoring of TPGF. During the course of its financial cooperation with TPGF, including deposit and loan arrangements, the Company will regularly obtain and review relevant operational information, legal information, statistical data, transaction data and financial data of TPGF, and assess its business and financial risks. The Company will prepare a continuous risk assessment report on a semi-annual basis, which will be submitted to the board of directors of the Company for approval and disclosed in accordance with applicable regulatory requirements. In the event that any abnormal circumstances are identified in respect of TPGF, the Company

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*

will promptly report to the board of directors of the Company and immediately initiate its risk response plan, so as to effectively prevent and mitigate the relevant risks, and safeguard the security of the Company's funds and the legitimate interests of all shareholders of the Company.
公司审慎核查财务公司的相关经营资质证件，充分了解财务公司机构设置、制度建设、经营运行等相关信息，强化对财务公司的风险评估与动态管理工作。在与财务公司开展存贷款等金融业务合作期间，公司将定期取得并审阅财务公司的相关运营信息、法律信息、统计数据、交易和财务数据等信息，评估财务公司的业务与财务风险，每半年编制风险持续评估报告，报公司董事会审议通过并履行信息披露义务。若发现财务公司出现异常情况，公司将第一时间向董事会报告，并立即启动风险处置预案，切实防范化解相关风险，保障公司资金安全及全体股东的合法权益。

6. OPINIONS ON RISK ASSESSMENT
风险评估意见

In view of the analysis and assessment as set out above, the Company is of the view that:
基于以上分析与判断，本公司认为：

(a) TPGF holds a valid financial licence and a valid business licence;
财务公司具有合法有效的《金融许可证》、《营业执照》；

(b) TPGF has established a relatively complete and sound internal control system which is capable of effectively controlling risks, and all relevant indicators comply with the regulatory requirements;
财务公司建立了较为完整合理的内部控制制度，能较好地控制风险，各项指标符合监管要求规定；

(c) since its incorporation, TPGF has been operating in accordance with the Administrative Measures, and no material defects have been identified in the risk management of TPGF;
财务公司成立至今严格按照《企业集团财务公司管理办法》的规定经营，财务公司的风险管理不存在重大缺陷；

(d) TPGF operates in compliance with applicable laws and regulations, maintains adequate liquidity, has a sound internal control system and good asset quality. Its capital adequacy ratio meets regulatory requirements and its provisions are adequate. The risk associated with the financial transactions currently conducted between the Company and TPGF, including deposits and loans, are controllable; and
财务公司运营合规，资金充裕，内部控制健全，资产质量良好，资本充足率达到监管要求，拨备充足，目前公司与财务公司之间发生的关联存、贷款等金融业务风险可控。

(e) the financial transactions between the Company and TPGF comply with the requirements of the relevant regulatory authorities, including the NFRA, the China Securities Regulatory Commission and the Shanghai Stock Exchange, and are also in line with the relevant provisions of the Company's internal policies.
本公司与财务公司之间的金融业务符合国家金融监督管理总局、中国证券监督管理委员会和上海证券交易所等监管机构的要求，符合本公司内部制度的相关规定。

Disclaimer: *The English version of the Continuous Risk Assessment Report of Tianjin Pharmaceutical Group Finance Co., Ltd. has been translated from the original Chinese text for reference only. In the event of any discrepancy, conflict or inconsistency between the English and Chinese versions, the Chinese version shall prevail.*